Orchard Therapeutics plc (ORTX)
Jan 24, 2024 - ORTX was delisted (reason: acquired by Kyowa Kirin)
16.70
0.00 (0.00%)
Inactive · Last trade price on Jan 23, 2024
Orchard Therapeutics Stock Forecast
Stock Price Forecast
The 3 analysts with 12-month price forecasts for Orchard Therapeutics stock had an average target of 21.67, with a low estimate of 15 and a high estimate of 34.
Price Target: $21.67 (+29.76%)
Analyst Consensus: Buy
* Price targets were last updated on Oct 5, 2023.
Analyst Ratings
The average analyst rating for Orchard Therapeutics stock from 3 stock analysts was "Buy". This means that analysts believed this stock was likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Aug '23 | Sep '23 | Oct '23 | Nov '23 | Dec '23 | Jan '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Buy | 2 | 2 | 2 | 2 | 2 | 2 |
| Hold | 0 | 0 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 2 | 2 | 3 | 3 | 3 | 3 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Stifel | Stifel | Strong Buy → Hold Downgrades $16 | Strong Buy → Hold | Downgrades | $16 | -4.19% | Oct 5, 2023 |
| Oppenheimer | Oppenheimer | Buy Reiterates $34 | Buy | Reiterates | $34 | +103.59% | Aug 9, 2023 |
| Cantor Fitzgerald | Cantor Fitzgerald | Buy Reiterates $15 | Buy | Reiterates | $15 | -10.18% | Jun 27, 2023 |
| Oppenheimer | Oppenheimer | Buy Maintains $37 → $34 | Buy | Maintains | $37 → $34 | +103.59% | Jun 13, 2023 |
| Cantor Fitzgerald | Cantor Fitzgerald | Buy Maintains $3 → $15 | Buy | Maintains | $3 → $15 | -10.18% | Mar 28, 2023 |
Financial Forecast
Revenue This Year
26.37M
from 22.66M
Increased by 16.38%
Revenue Next Year
46.60M
from 26.37M
Increased by 76.76%
EPS This Year
-1.68
from -11.80
EPS Next Year
-1.96
from -1.68
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|
| High | 31.3M | 59.5M | 131.7M | |||
| Avg | 26.4M | 46.6M | 98.9M | |||
| Low | 19.3M | 21.9M | 67.0M |
Revenue Growth
| Revenue Growth | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|
| High | 38.1% | 125.6% | 182.6% | |||
| Avg | 16.4% | 76.8% | 112.1% | |||
| Low | -14.8% | -17.1% | 43.8% |
EPS Forecast
| EPS | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|
| High | -0.42 | -0.39 | -0.33 | ||
| Avg | -1.68 | -1.96 | -0.32 | ||
| Low | -2.83 | -4.88 | -0.30 |
EPS Growth
| EPS Growth | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.